YLR412C-A Antibody

What is YLR412C-A protein and why is it studied in research?

YLR412C-A is an uncharacterized protein found in Saccharomyces cerevisiae (baker's yeast), specifically in the strain 204508/S288c. Despite being categorized as "uncharacterized," this protein has significance in yeast biology research as part of efforts to understand the complete yeast proteome. Studying uncharacterized proteins like YLR412C-A is essential for filling knowledge gaps in yeast systems biology and can provide insights into conserved cellular mechanisms across eukaryotes.

The protein is referred to as "hypothetical" in some databases, which indicates that its existence has been predicted through genomic analysis, but experimental verification of its expression and function may still be limited . Researchers typically study such proteins to determine their cellular localization, identify potential binding partners, characterize their function in cellular pathways, and investigate evolutionary conservation across fungal species.

What types of YLR412C-A antibodies are available for research purposes?

Based on the available information, researchers can access at least one type of YLR412C-A antibody:

• Rabbit anti-Saccharomyces cerevisiae YLR412C-A Polyclonal Antibody: This antibody is raised in rabbits against the YLR412C-A protein and purified using antigen-affinity techniques. It has been validated for ELISA and Western blot applications .

When selecting an antibody for YLR412C-A research, consider whether monoclonal or polyclonal antibodies better suit your research needs, the host species (rabbit in this case) and potential cross-reactivity concerns, the purification method (antigen-affinity purified antibodies typically offer higher specificity), and validated applications (ELISA and Western blot for the rabbit polyclonal) .

What are the common applications for YLR412C-A antibodies in yeast research?

YLR412C-A antibodies have been validated for the following applications:

• Western Blot (immunoblotting): For detecting YLR412C-A protein in yeast cell lysates, allowing quantification and size determination.

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of YLR412C-A in solution .

Researchers may also explore other common antibody applications, though these would require additional validation:

• Immunoprecipitation (IP): To isolate YLR412C-A and potential binding partners.

• Immunofluorescence (IF): To visualize the cellular localization of YLR412C-A.

• ChIP (Chromatin Immunoprecipitation): If YLR412C-A is found to have DNA-binding properties.

When using YLR412C-A antibodies for these applications, appropriate controls must be included to ensure specificity and accuracy of results .

How can I validate the specificity of YLR412C-A antibodies for my research?

Validating antibody specificity is crucial for reliable research outcomes. For YLR412C-A antibodies, consider these validation methods:

• Genetic validation:

  • Use YLR412C-A knockout strains as negative controls

  • Compare antibody reactivity in wild-type versus knockout lysates by Western blot

  • Expect absence of signal in knockout samples if the antibody is specific

• Overexpression validation:

  • Create strains overexpressing tagged YLR412C-A

  • Verify antibody detection of increased protein levels

  • Confirm co-localization of antibody signal with tag-specific antibodies

• Peptide competition assay:

  • Pre-incubate antibody with excess YLR412C-A peptide/protein

  • Specific antibodies will show reduced or absent signal after peptide blocking

  • Non-specific binding will remain unchanged

• Cross-reactivity assessment:

  • Test antibody against lysates from related yeast species

  • Evaluate signal in closely related proteins to assess off-target binding

Document all validation experiments thoroughly, including both positive and negative results, to establish confidence in antibody specificity .

What controls should I include when working with YLR412C-A antibodies?

Proper controls are essential for interpreting results with YLR412C-A antibodies:

Essential controls for Western blotting:

• Positive control: Lysate from wild-type S. cerevisiae expressing YLR412C-A

• Negative control: Lysate from YLR412C-A knockout strain

• Loading control: Detection of a housekeeping protein (e.g., actin or GAPDH)

• Primary antibody control: Omit primary antibody but include secondary antibody

• Secondary antibody control: Omit secondary antibody but include primary antibody

Essential controls for ELISA:

• Antigen dilution series for standard curve

• Blank wells (no antigen, with antibodies)

• Negative control (irrelevant antigen)

• Background control (no primary antibody)

For immunofluorescence (if applicable):

• No primary antibody control

• Non-specific IgG control (same species as primary antibody)

• YLR412C-A knockout strain

• DAPI staining for nuclear localization

Including these controls helps distinguish specific signals from background and ensures confidence in the antibody's performance and specificity .

How can I assess and address batch-to-batch variability in YLR412C-A antibodies?

Batch-to-batch variability is a common concern, particularly with polyclonal antibodies. To assess and mitigate this issue:

• Documentation and record-keeping:

  • Always record antibody batch/lot numbers in your laboratory notebook

  • Include batch information in publications as recommended by reporting guidelines

• Comparative validation:

  • When receiving a new batch, run side-by-side tests with the previous batch

  • Compare signal intensity, background, and specificity patterns

  • Document any differences observed between batches

• Standardization procedures:

  • Create a standard protocol for antibody validation in your lab

  • Establish acceptance criteria for new antibody batches

  • Prepare and freeze standard lysates as reference samples for batch testing

• Quantitative assessment:

  • Measure signal-to-noise ratios across batches

  • Determine detection limits for each batch

  • Create a calibration curve using recombinant YLR412C-A protein if available

• Bulk purchasing strategy:

  • When possible, purchase larger quantities of a single batch

  • Aliquot and store according to manufacturer recommendations

  • Use consistent aliquots across experimental series

If significant batch-to-batch variability is observed, consider switching to monoclonal antibodies (if available) or recombinant antibodies, which typically demonstrate better consistency across batches .

What are the optimal conditions for using YLR412C-A antibodies in Western blotting?

Optimizing Western blot conditions for YLR412C-A antibodies requires attention to several key parameters:

Sample preparation:

• Yeast cell lysis: Use glass bead disruption or enzymatic methods with appropriate protease inhibitors

• Protein extraction buffer: Typically RIPA or NP-40 based buffers with protease inhibitors

• Protein quantification: Bradford or BCA assay for equal loading

• Denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer with β-mercaptoethanol

Gel electrophoresis parameters:

• Gel percentage: 10-12% for optimal resolution of YLR412C-A

• Loading amount: 20-50 μg total protein per lane

• Running conditions: 100-120V constant voltage

Transfer conditions:

• Membrane: PVDF or nitrocellulose (0.45 μm pore size)

• Transfer method: Wet transfer at 100V for 1 hour or 30V overnight at 4°C

• Transfer buffer: Tris-glycine with 20% methanol

Blocking and antibody incubation:

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Start with 1:1000 dilution in 5% BSA in TBST, incubate overnight at 4°C

• Washing: 3-5 times with TBST, 5-10 minutes each

• Secondary antibody: Anti-rabbit HRP at 1:5000 in 5% milk-TBST, 1 hour at room temperature

• Final washing: 3-5 times with TBST, 5-10 minutes each

Detection:

• Enhanced chemiluminescence (ECL) detection

• Exposure time: Start with 30 seconds, adjust as needed

Optimization table for troubleshooting:

Always perform a dilution series for new antibodies to determine the optimal concentration for specific and sensitive detection .

How should I prepare yeast samples for immunostaining with YLR412C-A antibodies?

Immunostaining of yeast cells requires careful sample preparation to maintain cellular structure while allowing antibody access:

Fixation and spheroplasting protocol:

• Culture preparation:

  • Grow yeast to mid-log phase (OD600 of 0.5-0.8)

  • Harvest cells by centrifugation (3,000 × g for 5 minutes)

• Fixation:

  • Resuspend cells in fixation buffer (4% formaldehyde in PBS)

  • Incubate for 30-60 minutes at room temperature

  • Wash cells 3 times with PBS

• Cell wall digestion (spheroplasting):

  • Resuspend cells in spheroplasting buffer (1.2 M sorbitol, 0.1 M potassium phosphate, pH 7.4)

  • Add zymolyase (100T at 5-10 μg/ml) or lyticase

  • Incubate at 30°C for 30-60 minutes, monitoring spheroplasting progress microscopically

  • Wash gently 3 times with spheroplasting buffer

• Permeabilization:

  • Resuspend spheroplasts in permeabilization buffer (1.2 M sorbitol, PBS, 0.1% Triton X-100)

  • Incubate for 5 minutes at room temperature

  • Wash 3 times with spheroplasting buffer

• Blocking:

  • Block with 5% BSA in PBS for 30-60 minutes

• Antibody incubation:

  • Primary antibody: Use anti-YLR412C-A antibody at 1:100-1:500 dilution in blocking buffer

  • Incubate overnight at 4°C

  • Wash 3 times with PBS

  • Secondary antibody: Fluorescently labeled anti-rabbit IgG at 1:500-1:1000

  • Incubate for 1-2 hours at room temperature in the dark

  • Wash 3 times with PBS

• Mounting and imaging:

  • Mount in antifade medium containing DAPI for nuclear staining

  • Seal with nail polish

  • Store at 4°C in the dark until imaging

Alternative approaches:

• For co-localization studies, combine with GFP-tagged proteins or organelle markers

• For super-resolution microscopy, consider specialized fixation protocols

• For live-cell imaging, consider using fluorescently tagged YLR412C-A constructs instead of antibodies

What troubleshooting steps should I take if my YLR412C-A antibody isn't producing expected results?

When experiencing issues with YLR412C-A antibodies, follow this systematic troubleshooting approach:

For Western blot issues:

• No signal detected:

  • Verify protein transfer: Use Ponceau S staining

  • Check antibody activity: Test with a positive control

  • Increase antibody concentration: Try 2-5× higher concentration

  • Increase protein loading: Double the amount loaded

  • Extend exposure time: Try longer detection times

  • Verify expression: Confirm YLR412C-A is expressed in your samples

  • Check detection system: Test ECL reagents with another antibody

• High background:

  • Increase blocking: Try 5% BSA instead of milk, or extend blocking time

  • Decrease antibody concentration: Dilute primary and secondary antibodies

  • Increase washing: Add more wash steps or extend washing time

  • Try different blocking agents: Switch between milk, BSA, or commercial blockers

  • Clean membrane: Wash thoroughly before blocking

• Multiple bands or unexpected band size:

  • Validate antibody: Check with knockout controls

  • Check for degradation: Add more protease inhibitors

  • Look for post-translational modifications: Consider phosphorylation or glycosylation

  • Test different lysis conditions: Try native versus denaturing conditions

  • Check for alternate splicing: Review literature for isoforms

For immunostaining issues:

• No signal:

  • Optimize fixation: Test different fixatives (formaldehyde, methanol)

  • Improve permeabilization: Adjust detergent concentration

  • Increase antibody concentration: Try 2-5× higher concentration

  • Extend incubation time: Increase to 48 hours for primary antibody

  • Check antigen accessibility: Try antigen retrieval methods

• Non-specific staining:

  • Increase blocking: Try different blocking agents or concentrations

  • Dilute antibody further: Use more dilute antibody solutions

  • Pre-absorb antibody: Incubate with knockout lysate before use

  • Reduce autofluorescence: Include quenching steps

Systematic validation experiments:

• Confirm antibody functionality with positive controls

• Validate with genetic knockouts or overexpression systems

• Test different fixation and permeabilization conditions

• Try different detection methods

• Consult literature for specific protocols with similar proteins

Document all troubleshooting steps systematically to identify patterns and optimal conditions for future experiments .

How can I use YLR412C-A antibodies for studying protein-protein interactions?

YLR412C-A antibodies can be valuable tools for investigating protein-protein interactions through several advanced techniques:

1. Co-immunoprecipitation (Co-IP):

• Lyse yeast cells under non-denaturing conditions

• Incubate lysate with YLR412C-A antibody

• Capture antibody-protein complexes with Protein A/G beads

• Wash to remove non-specific interactions

• Elute and analyze interacting proteins by SDS-PAGE and mass spectrometry

• Confirm interactions with reciprocal Co-IP using antibodies against suspected partners

2. Proximity Ligation Assay (PLA):

• Fix and permeabilize yeast cells

• Incubate with YLR412C-A antibody and antibody against potential interacting protein

• Add PLA probes (oligonucleotide-linked secondary antibodies)

• Conduct ligation and amplification steps

• Visualize interaction as fluorescent spots using microscopy

• Quantify signals to assess interaction strength

3. Bimolecular Fluorescence Complementation (BiFC) as an antibody-free alternative:

• Create fusion constructs of YLR412C-A and suspected partners with split fluorescent protein fragments

• Express in yeast cells

• Visualize reconstituted fluorescence when proteins interact

• Use antibodies for validation via other methods

4. FRET (Förster Resonance Energy Transfer) analysis:

• Label YLR412C-A antibody with donor fluorophore

• Label partner protein antibody with acceptor fluorophore

• Analyze energy transfer as indicator of proximity

• Calculate FRET efficiency to determine interaction dynamics

5. Chromatin Immunoprecipitation (ChIP) for DNA interactions:

• If YLR412C-A has potential DNA-binding roles

• Cross-link proteins to DNA in vivo

• Immunoprecipitate with YLR412C-A antibody

• Identify bound DNA sequences by qPCR or sequencing

Key considerations:

• Always include appropriate negative controls (IgG, knockout strains)

• Validate interactions through multiple independent techniques

• Consider the effect of antibody binding on potential interaction interfaces

• Use mild lysis conditions to preserve native protein complexes

• Consider crosslinking to capture transient interactions

Can machine learning approaches improve YLR412C-A antibody-antigen binding prediction?

Machine learning approaches show promising potential for predicting antibody-antigen binding, which could be applied to YLR412C-A research:

Current applications of machine learning in antibody research:

• Binding affinity prediction:

  • Machine learning models can predict binding affinities between antibodies and their targets

  • These predictions can guide experimental design and antibody selection

  • For YLR412C-A research, this could help identify optimal epitopes for antibody development

• Epitope prediction:

  • Algorithms can predict likely binding sites on YLR412C-A

  • This can inform antibody design and selection

  • Both linear and conformational epitopes can be predicted

• Out-of-distribution prediction challenges:

  • As noted in the research literature, machine learning models face challenges when predicting interactions for antibodies and antigens not represented in training data

  • Active learning approaches can help address this limitation by iteratively expanding labeled datasets

• Library-on-library screening optimization:

  • Machine learning can improve efficiency of experimental screening

  • Recent research demonstrates that active learning strategies can reduce the required number of antigen mutant variants by up to 35%

  • This accelerates the antibody development and characterization process

Implementing machine learning for YLR412C-A antibody research:

• Data collection requirements:

  • Generate binding data for YLR412C-A with existing antibodies

  • Include both positive and negative binding results

  • Ensure diverse representation of antibody classes

• Feature engineering:

  • Extract sequence features from YLR412C-A and antibodies

  • Include structural predictions where available

  • Consider physicochemical properties

• Model selection:

  • Random forests, neural networks, and support vector machines have shown success

  • Ensemble methods often outperform single models

  • Models must be validated with experimental data

• Active learning strategy:

  • Start with small labeled dataset

  • Use model uncertainty to select next experiments

  • Iteratively refine model with new experimental results

  • This approach has been shown to speed up the learning process by 28 steps compared to random selection

Machine learning approaches could significantly improve research efficiency by reducing the experimental burden while enhancing antibody specificity and binding prediction for YLR412C-A research .

What are the latest techniques for improving YLR412C-A antibody specificity and sensitivity?

Researchers are employing several cutting-edge approaches to enhance antibody specificity and sensitivity, which can be applied to YLR412C-A antibodies:

Advanced antibody engineering techniques:

• Phage display technology:

  • Enables screening of large antibody libraries against YLR412C-A

  • Allows selection of high-affinity and high-specificity antibodies

  • Can be combined with negative selection strategies to remove cross-reactive antibodies

• Recombinant antibody development:

  • Production of recombinant YLR412C-A antibodies with defined sequences

  • Eliminates batch-to-batch variability seen in polyclonal antibodies

  • Enables engineering of binding domains for improved performance

• Single B cell cloning:

  • Isolation of B cells producing antibodies against YLR412C-A

  • Sequencing and cloning of antibody genes

  • Development of monoclonal antibodies with high specificity

• Antibody fragments and alternative scaffolds:

  • Development of Fab, scFv, or nanobody formats for improved tissue penetration

  • Creation of synthetic binding proteins based on non-antibody scaffolds

  • These smaller formats may access epitopes unavailable to full-size antibodies

Enhancement of detection sensitivity:

• Signal amplification strategies:

  • Tyramide signal amplification (TSA) for immunostaining

  • Polymer-based detection systems for Western blotting

  • Quantum dots as fluorescent labels for extended sensitivity range

• Multiplex detection systems:

  • Simultaneous detection of YLR412C-A and interacting partners

  • Use of different fluorophores or chromogens

  • Microarray-based detection platforms

• Super-resolution microscopy compatibility:

  • Development of antibodies optimized for STORM, PALM, or STED microscopy

  • Allows nanoscale localization of YLR412C-A in cellular contexts

Specificity improvement strategies:

• Epitope mapping and selection:

  • Identification of unique epitopes on YLR412C-A

  • Selection of antibodies targeting distinctive regions

  • Avoidance of conserved domains that could lead to cross-reactivity

• Negative depletion strategies:

  • Pre-adsorption of antibodies with related proteins

  • Removal of cross-reactive antibody populations

  • Sequential affinity purification techniques

• Validation across multiple platforms:

  • Comprehensive validation using orthogonal techniques

  • Correlation of results across different detection methods

  • Use of genetic knockout controls for absolute specificity confirmation

• Computational prediction and design:

  • Structure-based epitope prediction

  • In silico analysis of potential cross-reactivity

  • Rational design of antibodies with enhanced specificity

These advanced techniques can be applied to develop next-generation YLR412C-A antibodies with superior performance characteristics for research applications.

What information should I include when reporting YLR412C-A antibody use in publications?

Proper reporting of antibody use is crucial for experimental reproducibility. When publishing research involving YLR412C-A antibodies, include the following information:

Essential reporting elements:

• Antibody identification:

  • Complete antibody name and clone number (if monoclonal)

  • Host species and antibody type (polyclonal, monoclonal, recombinant)

  • Supplier name and location

  • Catalog number

  • Lot or batch number (especially important for polyclonal antibodies)

  • RRID (Research Resource Identifier) if available

• Validation information:

  • Methods used to validate specificity (Western blot, knockout controls, etc.)

  • References to previous validation studies, if applicable

  • Statement about observed versus expected molecular weight

  • Description of any observed cross-reactivity

• Experimental details:

  • Application used (Western blot, ELISA, immunofluorescence, etc.)

  • Antibody dilution or concentration used

  • Incubation conditions (time, temperature, buffer composition)

  • Detection method and reagents

  • Sample preparation methods

  • Blocking reagents and conditions

• Controls employed:

  • Positive and negative controls

  • Secondary antibody-only controls

  • Isotype controls where applicable

  • Knockout or knockdown validation if available

Example reporting format:
"YLR412C-A was detected using rabbit polyclonal anti-YLR412C-A antibody (Vendor X, catalog #Y123, lot #Z456, RRID:AB_123456) at 1:1000 dilution in 5% BSA/TBST overnight at 4°C. Antibody specificity was validated using parallel samples from wild-type and YLR412C-A knockout S. cerevisiae strains. Secondary detection was performed using HRP-conjugated goat anti-rabbit IgG (Vendor A, catalog #B789) at 1:5000 dilution for 1 hour at room temperature."

Additional considerations:

• Include representative images of full Western blots, including molecular weight markers

• Provide raw data in supplementary materials or public repositories

• Describe any image processing performed

• Note any batch-to-batch variability observed during the study

Following these reporting practices enhances experimental reproducibility and aligns with journal requirements, including those from the Nature Publishing Group, which has included antibody information in their Reporting Checklist for Life Science Articles .

How can I ensure reproducibility when using YLR412C-A antibodies across different experiments?

Ensuring reproducibility with YLR412C-A antibodies requires systematic approaches to experimental design, execution, and documentation:

Strategies for enhancing reproducibility:

• Standardized protocols:

  • Develop detailed standard operating procedures (SOPs)

  • Include all buffer compositions and preparation methods

  • Document exact incubation times and temperatures

  • Specify equipment settings and calibration status

• Antibody management:

  • Purchase larger quantities of single antibody batches when possible

  • Prepare aliquots to minimize freeze-thaw cycles

  • Store according to manufacturer's recommendations

  • Track antibody performance over time with control experiments

  • Document lot numbers and maintain lot-specific validation data

• Sample preparation consistency:

  • Standardize cell culture or yeast growth conditions

  • Use consistent lysis buffers and protocols

  • Implement rigorous protein quantification

  • Prepare and store samples in a consistent manner

• Controls and calibration:

  • Include standard positive and negative controls in every experiment

  • Prepare calibration standards for quantitative assays

  • Use internal reference samples across experimental batches

  • Implement loading controls appropriate for your application

• Quantification and analysis:

  • Use standardized image acquisition settings

  • Apply consistent image analysis protocols

  • Employ appropriate statistical methods

  • Consider blinding during analysis to reduce bias

Documentation practices for reproducibility:

• Comprehensive laboratory notebooks:

  • Record all experimental details, including unexpected observations

  • Note any deviations from standard protocols

  • Document instrument settings and calibration status

  • Include raw data and primary analysis

• Reagent tracking system:

  • Implement a system to track antibody aliquots and usage

  • Record performance across experiments

  • Note when new lots are introduced

  • Document comparative validation between lots

• Data management plan:

  • Establish consistent file naming conventions

  • Maintain organized raw data archives

  • Document analysis workflows and parameters

  • Preserve analysis scripts and software versions

Validation across experimental conditions:

• Multi-condition validation:

  • Test antibody performance across relevant experimental variables

  • Document detection limits under different conditions

  • Establish acceptable performance criteria

• Cross-platform validation:

  • Confirm findings using orthogonal techniques

  • Compare results from different detection methods

  • Validate key findings with alternative antibodies if available

• Collaborative validation:

  • Exchange protocols with collaborators

  • Implement cross-laboratory validation for critical findings

  • Address and document sources of variability between sites

By implementing these approaches, researchers can significantly enhance the reproducibility of experiments using YLR412C-A antibodies, improving both internal consistency and the ability of others to build upon your findings .